Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHOX2B PC-CAR T
- Development stage
- Phase 1
- Lead developer
- MyriO Tx
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PHOX2B PC-CAR T is a novel peptide-centric chimeric antigen receptor (PC-CAR) T cell therapy designed to target neuroblastoma. This therapy specifically recognizes a tumor-specific peptide derived from the transcriptional regulator and neuroblastoma dependency gene PHOX2B, presented on the surface of cancer cells by MHC molecules. Unlike traditional CAR-T therapies that target extracellular antigens, this approach enables targeting of intracellular oncoproteins previously considered "undruggable." Preclinical studies demonstrated complete and targeted elimination of neuroblastoma tumors in mouse models. The therapy is being developed by Myrio Therapeutics in collaboration with researchers at Children's Hospital of Philadelphia (CHOP), with first-in-human clinical trials now underway for relapsed or refractory neuroblastoma[1][3][4][6].
- Brand names
- PHOX2B PC-CAR TPHOX-2B PC-CAR TPHOX 2B PC-CAR T
- Other names
- PHOX2B CAR-TPHOX-2B CAR-TPHOX 2B CAR-TPHOX2B peptide-centric CAR-TPHOX-2B peptide-centric CAR-TPHOX 2B peptide-centric CAR-T
02
Targets
PHOX2B/HLA-A*24:02 (PHOX2B peptide-HLA-A*24:02 complex)PHOX2B (Paired-like homeobox 2b protein)
Beyond the preview
Go deeper on PHOX2B PC-CAR T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PHOX2B PC-CAR T.